


Neuroanesthesia in the Endovascular Suite


We Are Doing What In IR?? Are We Really A Stroke Center?




Paul Mongan MD

Neuro IR Issues

- System
 - IR Suite size
 - Organization
- Radiation Safety
- Procedures
- Coagulation



Neuro IR Issues



Health Phys. 2012 Jul;103(1):80-99.

Occupational radiation doses to operators performing fluoroscopically-guided procedures.

Kim KP, et al.

The estimated effective dose per case ranged from 0.1-101 μ Sv for vertebroplasty, 2.5-88 μ Sv for orthopedic extremity nailing, 2.0-46 μ Sv for biliary tract procedures, 2.5-74 μ Sv for TIPS, 1.8-53 μ Sv for head/neck endovascular therapeutic procedures, 0.2-49 μ Sv for ERCP.

Mean operator radiation dose per case measured over personal protective devices at different anatomic sites on the head and body ranged from 19-800 (median = 113) μ Sv at eye level, 6-1,180 (median = 75) μ Sv at the neck, 2-1,600 (median = 302) μ Sv at the trunk.

average annual U.S. radiation dose of 6.2 mSv.

Neuroendovascular Procedures

- Diagnostic
- Aneurysm Therapy
 - Coiling
 - Intracranial stent placement
 - Vasospasm management
- Carotid artery stenting
- Stroke Therapy
 - Clot-dissolution
 - Clot removal
- Embolization
 - arteriovenous malformation (AVM)
 - tumor

Subarachnoid Hemorrhage

- 57 yo female with SAH 4 hours ago
 - GCS 15
 - Headache with BP 140/76
 - No focal signs (mass effect)
 - No cranial nerve injury (jet effect)
- 6mm ACA aneurysm
- Clip or coil???

IR Suite vs. OR

- Location / anatomy of the aneurysm
- Age and grade of the patient
- Skill of the facility
- Skill of the proceduralist
- Luck of the draw???



Aneurysm Therapy

- **Surgical clipping** (approximately 60-65% in the United States)
- **Endovascular coiling** (approximately 30-35% in the United States)
- In certain countries such as Finland, Great Britain and France, close to 90% of aneurysms are treated with endovascular coiling
- After the release of the ISAT results, the percentage of aneurysm patients treated with coiling in England went from 40% to 90%



History of Coiling


- 1987-1989: Dr Guido Guglielmi (University of Rome) visits Dr Viñuela (IR Neuroradiologist) at UCLA and researches coiling
- 1989: Dr Guglielmi comes permanently to UCLA
- 1989-1990: Bench and animal research
- March 6, 1990: First clinical use of Guglielmi Detachable Coil
- FDA approval in 1995



International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized trial

The Lancet

Vol 360, October 26, 2002




Annual number at risk (deaths):

Endovascular	1073 (85)	974 (3)	887 (5)	717 (8)	541 (4)	373 (5)	215 (6)	103
Neurosurgery	1070 (105)	944 (10)	842 (16)	663 (3)	503 (3)	340 (7)	192 (3)	98

Figure 2 Kaplan Meier cumulative mortality to 7 years

Andrew J Molyneux, Richard SC Kerr, Ly-Mee Yu, Mike Clarke, Mary Sneade, Julia A Yamold, Peter Sandercock
 International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion
 The Lancet Volume 366, Issue 9488 2005 809 - 817
[http://dx.doi.org/10.1016/S0140-6736\(05\)67214-5](http://dx.doi.org/10.1016/S0140-6736(05)67214-5)



Annual number at risk (rebleeding):

Endovascular	1073 (45)	953 (1)	865 (1)	698 (0)	524 (3)	360 (2)	201 (0)	98
Neurosurgery	1070 (39)	926 (0)	821 (0)	652 (1)	495 (0)	332 (0)	188 (1)	95

Figure 3 Cumulative rebleeding risk from target aneurysm

Andrew J Molyneux, Richard SC Kerr, Ly-Mee Yu, Mike Clarke, Mary Sneade, Julia A Yamold, Peter Sandercock

International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion
 The Lancet Volume 366, Issue 9488 2005 809 - 817
[http://dx.doi.org/10.1016/S0140-6736\(05\)67214-5](http://dx.doi.org/10.1016/S0140-6736(05)67214-5)

ISAT Trial

- In patients with a ruptured intracranial aneurysm, for which endovascular coiling and neurosurgical clipping are therapeutic options, the outcome in terms of survival free of disability at 1 year is significantly better with endovascular coiling.
- The data available to date suggest that the long-term risks of further bleeding from the treated aneurysm are low with either therapy, although somewhat more frequent with endovascular coiling.



Neuroendovascular Concerns

- Maintain Physiological Stability
- Manage Anticoagulation
- Manipulate Systemic or Regional Blood Pressures
- Treat Unexpected Complications
- Rapid Recovery (neuro evaluation)



Anesthesia for Aneurysm Coiling

- GA with ETT (possible LMA) vs sedation
- Patient must NOT move
- Normocapnia and stable VS
- Arterial line
 - Radial
 - Side port on femoral
- Complications
 - Hemorrhage
 - ICP elevation
 - Ischemia



Emergent Angiography For Vasospasm

- Devastating complication of SAH
- Based on clinical criteria, transcranial doppler, ultrasound
- Irreversible damage can occur
- Time is critical, perfusion is critical
- Angioplasty
- Intra-arterial verapamil, nicardipine or papaverine can cause systemic effects

Rosenberg N, Lazzaro MA, Lopes DK, Prabhakaran S. High-dose intra-arterial nicardipine results in hypotension following vasospasm treatment in subarachnoid hemorrhage. Neurocrit Care. 2011 Dec;15(3):400-4. doi: 10.1007/s12028-011-9537-4. PubMed PMID: 21468780.



Neuroendovascular Procedures

- Diagnostic
- Aneurysm Therapy
 - Coiling
 - Intracranial stent placement
 - Vasospasm management
- **Carotid artery stenting**
- Stroke Therapy
 - Clot-dissolution
 - Clot removal
- Embolization
 - arteriovenous malformation (AVM)
 - tumor



CEA vs. Best Medical Therapy

Trial	Ipsilateral stroke, periop stroke, death	
	CEA	BMT
Nascet 70-99% (1991)	9%	26%
ECST 70-99% (1991)	9.5%	13.6%



CEA vs. Best Medical Therapy

Trial	Ipsilateral stroke, periop stroke, death	
	CEA	BMT
Nascet 50-69% (1998)	1.9%	7.0%
ECST 0-29% (1998)	11.3%	5.6%




Asymptomatic Carotid Atherosclerosis Study

- 1662 patients, 60-99% stenosis
- 1993-2002 with 10 year follow-up
- BMT vs BMT + CEA
- Study stopped after 2.7 years of follow-up
 - Ipsilateral stroke (5 year projected rate)
 - CEA + BMT 5.1%
 - BMT 11%



CEA vs CAS



Anesthesia for CAS

- Minimal to moderate sedation
 - Awake (very minimal sedation)
 - Propofol infusion
 - Dexmedetomidine infusion
- ACT monitoring
- Balloon dilation
 - Neck pain, cough
 - Bradycardia (25%)
 - Labile BP (20-50%)



Specialties Performing Carotid Stenting



specialty	percent
Interventional Cardiologist	60
Interventional Radiologist	15
Interventional Neuroradiologist	10
Interventional Neurosurgery	5
Interventional Vascular Surgery	5
Interventional Neurology	2
Interventional Medicine	3



Stroke Therapy

- Intravenous Thrombolysis
- Combined Intravenous and Intraarterial Thrombolysis
- Endovascular Thrombectomy (the Merci Retriever)
- Endovascular Thromboaspiration (the Penumbra System)
- Angioplasty and/or Stent Placement (Covidien Solitaire™ FR Revascularization Device)






Thrombolysis

- Therapy cannot be initiated within three hours
- tPA during the first three hours is not sufficient
- Interventional neuroradiologists can provide intra-arterial thrombolysis treatment
- When given locally this way, the tPA can be administered up to six hours after the onset of stroke symptoms

Anticoagulation

- Heparin
 - ACT monitoring
- P2Y12 inhibitors
- GIIb/IIIa inhibitors



Clopidogrel

- Onset: 4-6 hours (after loading dose with 8 x maintenance dose)
- Offset: 5-7 days
- Variable response: 25-30% of patients achieve less than 25% inhibition of platelet activity
- 2 step metabolism (CYP3A4 mediated) to active agent
- Binds irreversibly to P2Y12 receptor
 - P2Y12 Reaction Unit (PRU) monitoring

VerifyNow P2Y12 test

- literature advises waiting 5 to 7 days after stopping clopidogrel before surgery
- tested patient as soon as 3 days
 - percent inhibition less than 20%
 - P2Y12 Reaction Units (PRUs) greater than 235
- Blue top tube, 3.2% sodium citrate



New Oral Antiplatelet Drugs Adenosine Diphosphate-Receptor Antagonists


- Prasugrel
 - (Effient)
 - Thienopyridine
 - More rapid onset of action than clopidogrel
 - Irreversible inhibitor of the P2Y12 receptor
- Ticagrelor
 - (Brilinta)
 - Cyclo-pentyl-triazopyrimidine (CPTP)
 - More rapid onset of action than clopidogrel
 - Reversible inhibitor of the P2Y12 receptor



P2Y12 Platelet Inhibition Test

% Inhibition Threshold	PRU Threshold
10%	259
20%	237
30%	214
40%	187
50%	159
60%	131

A PRU of **208 or less** is recommended for patients receiving P2Y12 anti-platelet therapy.




Abciximab - ReoPro


- glycoprotein IIb/IIIa receptor antagonist
- platelet aggregation inhibitor
- short plasma half-life
- strong affinity for receptor on the platelets
 - may occupy some receptors for weeks
 - platelet aggregation gradually returns to normal about 96 to 120 hours after administration



AVM Embolization



AVM Embolization



AVM Embolization

- 3-5% serious complications
- distal migration of cement/beads/coils
 - can shut-down the AVM
 - acute ICP elevation
 - bleed
- Ischemic complications

Neuroendovascular Procedures

- Diagnostic
- Aneurysm Therapy
 - Coiling
 - Intracranial stent placement
 - Vasospasm management
- Stroke Therapy
 - Clot-dissolution
 - Clot removal
- Carotid artery stenting
- Embolization
 - arteriovenous malformation (AVM)
 - tumor

Disasters

- Vessel rupture and hemorrhage
- Vasospasm
- Occlusion
- Dissection
- Thromboembolism
- Stent misplacement
- Access site hematoma
- Arrhythmia
- Death

Questions

